Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA121-28 in Medullary Thyroid Carcinoma
NCT04787328Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ha121-28 in medullary thyroid carcinoma (MTC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
ha121-28
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT04787328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787328.